GOSS Gossamer Bio Inc

Price (delayed)

$0.1781

Market cap

$41.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.79

Enterprise value

$202.75M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an ...

Highlights
GOSS's gross profit has dropped by 55% year-on-year but it is up by 15% since the previous quarter
GOSS's revenue has shrunk by 55% YoY but it is up by 15% QoQ
The quick ratio has dropped by 65% year-on-year and by 18% since the previous quarter
GOSS's equity is down by 32% QoQ

Key stats

What are the main financial stats of GOSS

GOSS stock price

How has the Gossamer Bio stock price performed over time
Intraday
-5.42%
1 week
-15.63%
1 month
-49.17%
1 year
-85.87%
YTD
-94.25%
QTD
-45.78%

Financial performance

How have Gossamer Bio's revenue and profit performed over time
Revenue
$55.54M
Gross profit
$55.54M
Operating income
-$178.78M
Net income
-$180.4M
Gross margin
100%
Net margin
-324.8%
GOSS's gross profit has dropped by 55% year-on-year but it is up by 15% since the previous quarter
GOSS's revenue has shrunk by 55% YoY but it is up by 15% QoQ
The operating margin is up by 9% since the previous quarter
The net margin rose by 8% since the previous quarter

Price vs fundamentals

How does GOSS's price correlate with its fundamentals

Growth

What is Gossamer Bio's growth rate over time

Valuation

What is Gossamer Bio stock price valuation
P/E
N/A
P/B
N/A
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.65
GOSS's EPS is down by 5% since the previous quarter
GOSS's equity is down by 32% QoQ
GOSS's price to sales (P/S) is 91% lower than its last 4 quarters average of 9.1
GOSS's revenue has shrunk by 55% YoY but it is up by 15% QoQ

Efficiency

How efficient is Gossamer Bio business performance
GOSS's ROA is down by 27% since the previous quarter
Gossamer Bio's ROIC has decreased by 21% from the previous quarter
GOSS's ROS is up by 7% since the previous quarter

Dividends

What is GOSS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GOSS.

Financial health

How did Gossamer Bio financials performed over time
GOSS's total assets is 56% lower than its total liabilities
The quick ratio has dropped by 65% year-on-year and by 18% since the previous quarter
The current ratio has plunged by 61% YoY and by 17% from the previous quarter
The company's debt to equity has surged by 96% YoY and by 24% QoQ
GOSS's equity is down by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.